(PubMed) Muskiet FA, Fokkema MR, Schaafsma A, Boersma ER, Crawford MA
In participants with metabolic dysfunction-associated steatotic liver disease (MASLD), retatrutide demonstrated an 82.4% reduction in liver fat content [4]
Regular InBody tests, every two to four weeks, will allow you to monitor your progress accurately and make informed adjustments to your diet, exercise, and treatment protocols
At Nusbaum Medical Centers, weve designed our Cedar Knolls suite to function as a clinical sanctuary for the 490,000 residents navigating the fast-paced environment of Northern New Jersey
A randomized controlled trial published in NPJ Aging and Mechanisms of Disease found that NAD+ precursor treatment increased cellular NAD+ levels by 60% and improved physical performance measures by 25% in healthy older adults (Elhassan et al., 2019)
This secondary analysis focused on heart health in the first six months after participant randomization